Drug intelligence / Profile preview

BMC322

Development stage: Preclinical
Lead developer: Biomica
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

BMC322 is an investigational, rationally designed **four-strain live bacterial consortium** developed to reduce intestinal inflammation in inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Biomica selected constituent bacteria through functional metagenomic analysis of IBD-associated microbiome functions linked to lower inflammatory activity, intestinal-barrier integrity, and colonocyte function. In vitro work and preliminary dextran sulfate sodium-induced colitis mouse studies reported anti-inflammatory activity, faster recovery, lower disease-activity measures, and reduced fecal lipocalin-2. ([academic.oup.com](https://academic.oup.com/ibdjournal/article-abstract/27/Supplement_1/S38/6105518))

Beyond the preview

Go deeper on BMC322.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMC322.

Explore the full profile